Re-optimization Based Online Adaptive Radiotherapy of Bladder Cancer

  • End date
    Mar 29, 2026
  • participants needed
  • sponsor
    Varian, a Siemens Healthineers Company
Updated on 4 October 2022


This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Condition Muscle-Invasive Bladder Carcinoma
Treatment Varian Ethos Adaptive Radiation Therapy
Clinical Study IdentifierNCT05295992
SponsorVarian, a Siemens Healthineers Company
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Histologically proven bladder cancer
Urothelial carcinoma
Age ≥ 18 years
Stage T1b-T4AN0M0
TUR-B and PET-CT or CT of thorax/abdomen/pelvis within 8 weeks prior to inclusion
Suitable for radiotherapy
ECOG/WHO performance status 0-2
Written informed consent
For Cohort B, participant's must have normal organ and marrow function as defined
leukocytes ≥2,500/mcL
absolute neutrophil count ≥1,500/mcL
platelets ≥100,000/mcL
hemoglobin ≥9 g/dL
total bilirubin ≤ 1,5 ULN
alkaline phosphatase ≤2.5 × ULN
creatinine clearance <25 ml/min We recommend avoiding cisplatin for participants with creatinine clearance <50 ml/min
INR and aPTT £1.5 ULN

Exclusion Criteria

Prior pelvic radiation therapy
Inability to comply with the protocol
Presence of a hip prothesis
Grade 2 or greater baseline diarrhea
Uncontrolled inflammatory bowel disease (ulcerative colitis or Crohn's disease)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note